Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2007-12-31
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Group A - Lactated Ringer's replacement for blood loss and placebo eye drops
Group B - Lactated Ringer's replacement for blood loss and brimonidine eye drops
Group C - Albumin replacement for blood loss and placebo eye drops
Group D - Albumin replacement for blood loss and brimonidine eye drops
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational, Qualitative Study Assessing Eye Drop Administration
NCT05307081
Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution
NCT05938699
Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients
NCT00352807
Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
NCT00853970
Processed Amniotic Fluid (PAF) Drops After Photorefractive Keratectomy (PRK)
NCT04281004
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Lactated Ringer's replacement for blood loss and placebo eye drops
No interventions assigned to this group
B
Lactated Ringer's replacement for blood loss and brimonidine eye drops
No interventions assigned to this group
C
Albumin replacement for blood loss and placebo eye drops;
No interventions assigned to this group
D
Albumin replacement for blood loss and brimonidine eye drops
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Anticipated blood loss ≥ 1L
* Age 18-80 years old;
* ASA physical status I-III.
Exclusion Criteria
* Diabetic retinopathy;
* Heart failure or serious left ventricular dysfunction;
* Abnormal preoperative fundus examination;
* Creatinine \> 2 mg/dL;
* Patient refuses blood transfusion or albumin administration
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Cleveland Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel I Sessler, MD
Role: STUDY_CHAIR
The Cleveland Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cleveland Clinic
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-571
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.